Phone: +43 1 25077-4460, +43 676 603 2478
Mrs. Mag. Dr. Eva Prieschl-Grassauer
Mr. Dipl.-Kfm. Pascal Schmidt
The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners.
The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose.
|04/16/2020||Annual financial statements 2019|
|05/26/2020||1st quarter 2020|
|08/27/2020||1st half year 2020|
|09/07/2020||Record date "Annual General Meeting"|
|09/14-18||Digital Austrian Investor Week|
|09/17/2020||Annual General Meeting|
|11/26/2020||3rd quarter 2020|
Source: provided by the company
Record date "Dividends": Date on which settled positions are struck in the books of the Issuer`s CSD at close of business to determine the entitlement to dividends. Origination of entitlement is still linked to the Ex-dividend date.
Record date "Annual General Meeting": Date for participation to Annual General Meeting.
Only eletronically delivered documents from OeKB since 18.04.2008.